Chemo plus immunotherapy before surgery for bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether giving chemotherapy (gemcitabine and cisplatin) combined with immunotherapy (pembrolizumab) before and after surgery can improve outcomes compared to having surgery right away. It is for people with bile duct cancer that can be removed or is borderline removable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of bile duct cancer (called perihilar or distal cholangiocarcinoma) that can be surgically removed or is borderline removable.
- You are at least 18 years old.
- Your daily activity level is good (ECOG score 0 or 1).
- If you have a blocked bile duct, it must have been successfully drained before starting the trial.
- You have not had prior treatment with immunotherapy drugs like pembrolizumab or similar medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and immunotherapy before surgery for locally advanced bile duct cancer. The goal is to see if this approach can shrink the tumor enough to improve surgical outcomes.
This trial tests a combination of chemotherapy drugs (gemcitabine, cisplatin, nab-paclitaxel) with an immunotherapy (rilvegostomig) before and after surgery for intrahepatic cholangiocarcinoma that can be completely removed. It aims to see if this approach improves outcomes.
This trial tests whether pembrolizumab combined with gemcitabine and cisplatin given around the time of surgery can improve outcomes for people with high-risk, potentially operable intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help by strengthening the immune system while also treating the cancer with chemotherapy.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug (pembrolizumab) given before and after surgery for people with bile duct or gallbladder cancer that can be removed. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests a combination of chemotherapy, an immunotherapy drug (adebrelimab), and a drug to boost white blood cells (mecapegfilgrastim) before surgery for people with biliary tract cancer. The goal is to see if this approach can shrink the tumor enough to make surgery possible.
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
Hear when a new Extrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.